Immunogen EVP John Lambert Sells 4,375 Shares (IMGN)
Immunogen (NASDAQ:IMGN) EVP John Lambert unloaded 4,375 shares of the company’s stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $14.53, for a total transaction of $63,568.75. Following the completion of the sale, the executive vice president now directly owns 106,857 shares of the company’s stock, valued at approximately $1,552,632. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
A number of research firms have recently commented on IMGN. Analysts at Zacks upgraded shares of Immunogen from a “neutral” rating to an “outperform” rating in a research note to investors on Friday, December 27th. They now have a $16.60 price target on the stock. Separately, analysts at Morgan Stanley downgraded shares of Immunogen from an “equal weight” rating to an “underweight” rating in a research note to investors on Monday, November 11th. They now have a $9.50 price target on the stock. Finally, analysts at RBC Capital cut their price target on shares of Immunogen from $22.00 to $18.00 in a research note to investors on Friday, November 8th. They now have an “outperform” rating on the stock. Two research analysts have rated the stock with a sell rating, four have given a hold rating and seven have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $17.26.
Immunogen (NASDAQ:IMGN) traded up 0.21% during mid-day trading on Monday, hitting $14.65. 211,847 shares of the company’s stock traded hands. Immunogen has a 52-week low of $12.55 and a 52-week high of $20.25. The stock’s 50-day moving average is $14.61 and its 200-day moving average is $16.42. The company’s market cap is $1.251 billion.
Immunogen (NASDAQ:IMGN) last released its earnings data on Friday, October 25th. The company reported ($0.13) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.23) by $0.10. The company had revenue of $17.20 million for the quarter, compared to the consensus estimate of $12.10 million. During the same quarter in the previous year, the company posted ($0.30) earnings per share. The company’s revenue for the quarter was up 319.5% on a year-over-year basis. On average, analysts predict that Immunogen will post $-0.75 earnings per share for the current fiscal year.
ImmunoGen, Inc (NASDAQ:IMGN) develops targeted, antibody-based therapeutics for the treatment of cancer.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.